Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

genedrive plc

Healthcare GB GDR

1.325GBX
0.07(6.00%)

Last update at 2026-06-05T15:22:00Z

Day Range

1.201.40
LowHigh

52 Week Range

0.191.88
LowHigh

Fundamentals

  • Previous Close 1.25
  • Market Cap15.25M
  • Volume3288437
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-5.38300M
  • Revenue TTM1.17M
  • Revenue Per Share TTM0.002
  • Gross Profit TTM -3.33400M
  • Diluted EPS TTM-0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -5.42600M -7.75000M -5.98100M -5.63100M -1.85200M
Minority interest - - - - -
Net income -5.23100M -7.07500M -5.15000M -4.67500M -0.69100M
Selling general administrative 2.10M 1.64M 1.35M 1.79M 1.66M
Selling and marketing expenses - - - - -
Gross profit 0.76M 0.25M 0.06M -3.82200M -3.82200M
Reconciled depreciation 0.07M 0.25M 0.25M 0.25M 0.25M
Ebit -5.42600M -7.73800M -5.19400M -5.61500M -5.48100M
Ebitda -5.35900M -7.49100M -4.94000M -5.36500M -5.23500M
Depreciation and amortization 0.07M 0.25M 0.25M 0.25M 0.25M
Non operating income net other - - - - -
Operating income -5.38000M -5.31200M -5.19400M -5.61500M -5.48200M
Other operating expenses 6.33M 5.81M 5.28M 5.66M 6.17M
Interest expense 0.00000M 0.01M 0.03M 0.02M 0.23M
Tax provision -0.19500M -0.67500M -0.83100M -0.95600M -1.16100M
Interest income 0.04M 0.03M 0.03M 0.00000M 0.00100M
Net interest income -0.04600M -0.54800M -0.00100M -0.01600M -0.23400M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.19500M -0.67500M -0.83100M -0.95600M -1.16100M
Total revenue 0.76M 0.50M 0.06M 0.05M 0.69M
Total operating expenses 6.14M 5.81M 5.28M 5.66M 6.17M
Cost of revenue - 0.25M - 3.87M 4.51M
Total other income expense net -0.04600M -2.43800M -0.78700M -0.01600M 3.63M
Discontinued operations - - - - -
Net income from continuing ops -5.23100M -7.07500M -5.15000M -4.67500M -0.69100M
Net income applicable to common shares - - - -4.67500M -0.69100M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 2.81M 6.80M 4.51M 6.62M 4.88M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets - 0.93M - 1.08M 1.40M
Total liab 1.38M 1.44M 2.47M 1.01M 1.28M
Total stockholder equity 1.44M 5.36M 2.04M 5.61M 3.59M
Deferred long term liab - - - - -
Other current liab 0.79M 0.76M 1.29M 0.84M 0.85M
Common stock 9.37M 8.15M 1.49M 1.39M 0.95M
Capital stock 9.37M 8.15M 1.49M 1.39M 0.95M
Retained earnings -65.17100M -57.44400M -52.22100M -47.07100M -42.35800M
Other liab - - - - -
Good will - - - - -
Other assets - - - - 0.05M
Cash 1.18M 5.19M 2.60M 4.59M 2.57M
Cash and equivalents - - - - -
Total current liabilities 1.38M 1.44M 2.45M 1.01M 1.28M
Current deferred revenue - - - -0.83700M -0.84600M
Net debt -1.18200M -5.16900M -2.36000M -4.57300M -2.45500M
Short term debt - 0.02M 0.22M 0.02M 0.12M
Short long term debt - - - - -
Short long term debt total - 0.02M 0.24M 0.02M 0.12M
Other stockholder equity 54.73M 54.66M 52.78M 45.68M 41.41M
Property plant equipment - - - 0.21M 0.30M
Total current assets 2.69M 6.63M 4.12M 6.42M 4.53M
Long term investments - - - - -
Net tangible assets - - - 5.61M 3.59M
Short term investments - - - - -
Net receivables 1.07M 0.12M 0.16M 1.06M 1.32M
Long term debt - - - - -
Inventory 0.43M 0.38M 0.53M 0.75M 0.56M
Accounts payable 0.59M 0.67M 0.94M 0.99M 1.17M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 2.50M - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - -0.20600M -0.30100M
Deferred long term asset charges - - - - -
Non current assets total 0.13M 0.17M 0.39M 0.21M 0.35M
Capital lease obligations 0.00000M 0.02M 0.24M 0.02M 0.12M
Long term debt total - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments - 0.00100M -0.00800M 0.03M 0.00100M
Change to liabilities - - - -0.29200M -1.03000M
Total cashflows from investing activities -0.02300M 0.00100M - 0.03M 0.00100M
Net borrowings - - - -0.11900M -0.50200M
Total cash from financing activities 1.12M 6.36M 1.82M 6.58M -0.45600M
Change to operating activities - - - - -
Net income -5.42600M -5.31200M -5.22400M -5.61500M -5.48200M
Change in cash -4.00600M 2.59M -1.98800M 2.02M -5.64400M
Begin period cash flow 5.19M 2.60M 4.59M 2.57M 8.22M
End period cash flow 1.18M 5.19M 2.60M 4.59M 2.57M
Total cash from operating activities -5.10100M -3.76800M -3.80500M -4.59400M -5.15200M
Issuance of capital stock 1.23M 6.25M 1.69M 6.69M 0.05M
Depreciation 0.07M 0.25M 0.25M 0.25M 0.25M
Other cashflows from investing activities - 0.03M - 0.09M 0.10M
Dividends paid - - - - -
Change to inventory -0.04700M 0.14M 0.22M -0.19200M -0.14300M
Change to account receivables -0.29700M -0.22400M - 0.05M 0.24M
Sale purchase of stock - - - - -
Other cashflows from financing activities -0.01900M 0.11M 0.14M -0.11900M -0.14400M
Change to netincome - - - 0.26M -3.58800M
Capital expenditures 0.02M 0.03M 0.05M 0.06M 0.10M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.38900M 0.41M 0.11M -0.43300M -0.93300M
Stock based compensation 0.08M 0.06M 0.10M 0.04M 0.00400M
Other non cash items 0.56M 0.83M 0.96M -0.16900M -0.00500M
Free cash flow -5.12400M -3.79700M -3.85700M -4.65600M -5.25600M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
GDR
genedrive plc		 0.07 6.00% 1.32 - 12.38 12.99 10.61 16.54 -6.0473
IDHC
Integrated Diagnostics Holdings PLC		 0.02 3.77% 0.55 0.20 12.89 3.33 6.89 3.22 8.79
HVO
hVIVO plc		 0.45 5.36% 8.85 7.05 18.32 0.89 1.01 0.69 2.93
ABDX
Abingdon Health Plc		 -0.75 5.88% 12.00 - 53.19 2.19 3.19 1.81 -0.2499
CLBX
CelLBxHealth plc		 -0.125 6.49% 1.80 - - 7.05 1.50 6.07 -1.6211

Reports Covered

Stock Research & News

View All

Profile

genedrive plc engages in the design, development, and manufacture of molecular diagnostics testing equipment for use in genotyping, pathogen detection, infectious disease detection, and other clinical indications. The company provides Genedrive system, rapid nucleic acid thermocycler and fluorescence signal detection system for target discrimination used for qualitative in vitro molecular diagnostic tests; and Genedrive CYP2C19 ID Kit, a certified test for identification of individuals unlikely to respond to the commonly prescribed antiplatelet drug Clopidogrel. It also offers Genedrive MT-RNR1-ID Kit, a rapid genetic test in an emergency neonatal care setting; and tests for the detection of Antibiotic Induced Hearing Loss in neonates, confirmation of HCV infection prior to drug administration, pathogen detection of biological military threats and a point-of-care for COVID-19 detection system for use in areas, such as healthcare, workplace screening, travel requirements, and confirmation of antigen tests. It serves medical, biotechnology, and pharmaceutical industries in the United Kingdom, Europe, the United States, and internationally. The company was formerly known as Epistem Holdings Plc and changed its name to genedrive plc in July 2016. The company was founded in 2000 and is headquartered in Manchester, the United Kingdom.

genedrive plc

The Incubator Building, Manchester, United Kingdom, M13 9XX

Key Executives

Name Title Year Born
Mr. David Budd CEO & Exec. Director 1968
Mr. Russell John Shaw Chief Financial Officer & Director 1978
Dr. Gino Miele Ph.D. CEO, Chief Scientific Officer & Executive Director 1970
Mr. Russell John Shaw CFO, Secretary & Director 1978

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions